CTOs on the Move

Cardiff Oncology

www.cardiffoncology.com

 
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cardiff Oncology raised $13.5M on 06/16/2020

Similar Companies

Wolfe Laboratories

Wolfe Laboratories is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Juneau Biosciences

Juneau Biosciences is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Biomolecule Corporation

Integrated Biomolecule Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bridge Medicines

Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.